Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
Upturn AI SWOT - About
Invesco Dynamic Pharmaceuticals ETF (PJP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/04/2025: PJP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type ETF | Historic Profit 20.63% | Avg. Invested days 68 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | ETF Returns Performance  4.0 |
| Profits based on simulation | Last Close 11/04/2025 |
Key Highlights
Volume (30-day avg) - | Beta 0.45 | 52 Weeks Range 72.01 - 89.04 | Updated Date 06/29/2025 |
52 Weeks Range 72.01 - 89.04 | Updated Date 06/29/2025 |
Upturn AI SWOT
Invesco Dynamic Pharmaceuticals ETF
ETF Overview
Overview
The Invesco Dynamic Pharmaceuticals ETF (PJP) is designed to provide investment results that generally correspond to the price and yield of the Dynamic Pharmaceutical Intellidex Index. The fund invests in companies involved in the research, development, manufacturing, and marketing of pharmaceuticals and drugs.
Reputation and Reliability
Invesco is a well-established and reputable global investment management firm with a long track record of providing diverse investment solutions.
Management Expertise
Invesco's management team possesses substantial experience in investment management, including expertise in sector-specific and index-tracking strategies.
Investment Objective
Goal
To track the investment results of the Dynamic Pharmaceutical Intellidex Index.
Investment Approach and Strategy
Strategy: PJP aims to replicate the performance of the Dynamic Pharmaceutical Intellidex Index through a full replication or representative sampling technique.
Composition The ETF's portfolio consists primarily of common stocks of US pharmaceutical companies.
Market Position
Market Share: Data not readily available.
Total Net Assets (AUM): 250000000
Competitors
Key Competitors
- XBI
- IBB
- XLV
Competitive Landscape
The pharmaceutical ETF market is competitive, with IBB and XBI holding larger market shares. PJP differentiates itself through its 'Intellidex' methodology which selects stocks based on fundamental and technical analysis, potentially offering higher growth but also introducing greater stock-specific risk compared to broader, market-cap-weighted ETFs. The fund's higher expense ratio may be a disadvantage.
Financial Performance
Historical Performance: Historical data including returns, volatility, and correlation are not readily available for inclusion.
Benchmark Comparison: Comparison data is not readily available for inclusion.
Expense Ratio: 0.56
Liquidity
Average Trading Volume
The average daily trading volume indicates moderate liquidity for PJP.
Bid-Ask Spread
The bid-ask spread is generally competitive and reflects market demand.
Market Dynamics
Market Environment Factors
PJP is influenced by factors such as FDA approvals, drug pricing regulations, patent expirations, and overall healthcare spending trends.
Growth Trajectory
The growth trajectory is dependent on the pharmaceuticals industry's innovation pipeline, regulatory environment, and broader economic conditions. Changes to strategy and holdings will be based on the Index provideru2019s rebalancing rules.
Moat and Competitive Advantages
Competitive Edge
PJP's 'Intellidex' methodology offers a potentially unique approach to selecting pharmaceutical stocks, aiming to identify those with the strongest growth potential. However, this also means more frequent turnover and a greater focus on smaller companies. This approach can lead to enhanced returns in favorable market conditions or underperformance if the selection criteria fail. Invesco's solid reputation as an ETF provider also bolsters investor confidence.
Risk Analysis
Volatility
PJP may exhibit higher volatility compared to broader market ETFs due to its concentration in the pharmaceutical sector and its unique selection methodology.
Market Risk
PJP is exposed to market risk, including sector-specific risks related to regulatory changes, drug trial failures, and competitive pressures within the pharmaceutical industry.
Investor Profile
Ideal Investor Profile
PJP is suitable for investors seeking targeted exposure to the pharmaceutical sector and those comfortable with potentially higher volatility in exchange for potential outperformance.
Market Risk
PJP may be best suited for investors with a moderate to high risk tolerance and those with a long-term investment horizon.
Summary
The Invesco Dynamic Pharmaceuticals ETF (PJP) offers targeted exposure to the pharmaceutical sector through its 'Intellidex' stock selection methodology. The expense ratio is relatively higher than broader market ETFs. It is suitable for investors seeking growth within the pharmaceutical space and who are comfortable with higher volatility. Before investing, investors should consider their risk tolerance and investment objectives to determine if PJP aligns with their overall portfolio strategy.
Similar ETFs
Sources and Disclaimers
Data Sources:
- Invesco Official Website
- ETF.com
- Yahoo Finance
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Market share estimations are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Invesco Dynamic Pharmaceuticals ETF
Exchange NYSE ARCA | Headquaters - | ||
IPO Launch date - | CEO - | ||
Sector - | Industry - | Full time employees - | Website |
Full time employees - | Website | ||
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index is composed of common stocks of U.S. pharmaceutical companies. These companies are engaged principally in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The fund is non-diversified.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.